THE TGA has granted a new indication for Jardiance 10mg (empagliflozin) that will enable a broader group of patients with chronic kidney disease (CKD) to receive SGLT-2 inhibitor therapy than before.
Jardiance 10mg is now indicated and available on private prescription to reduce the risk of kidney disease progression in adults with chronic kidney disease.
This applies to CKD Stages 2 and 3A with urine albumin to creatinine ratio [ACR] 30 mg/g, or CKD Stages 3B, four and five, irrespective of urine ACR.
According to Prof Carol Pollock, Renal Physician at Royal North Shore Hospital in Sydney, this milestone not only expands the group of kidney disease patients eligible for SGLT-2 inhibitor therapy to slow disease progression but supports screening for early detection as "intervention is shown to be beneficial in patients with early disease".
"For patients with emerging signs of kidney damage, the ability to commence treatment earlier, when there is the greatest potential to stabilise or delay the decline of kidney function, shows the public health benefits are likely to be significant," added Pollock. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Feb 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Feb 24
